Efficacy of inhaled corticosteroids in asthma

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 4 II, 1998, Pages 531-538

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway hyperresponsiveness; Asthma; Corticosteroids; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; BUDESONIDE; BUTIXOCORT; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; FORMOTEROL; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MIFEPRISTONE; MOMETASONE FUROATE; RU 24858; RU 40066; SALMETEROL; THEOPHYLLINE; TIPREDANE; TRIAMCINOLONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHUS HYPERREACTIVITY; CHILD; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; TOPICAL DRUG ADMINISTRATION;

EID: 0031764410     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(98)70268-4     Document Type: Article

References (45)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332:868-75.
2. Barnes PJ. Antiinflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94:557-72.
3. Schweibert LM, Stellato C, Schleimer RP. The epithelium as a target for glucocorticoid action in the treatment of asthma. Am J Respir Crit Care Med 1996;154:S16-20.
4. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 1990;141:S70-6.
5. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues in the use of inhaled steroids. Am J Respir Crit Care Med 1996;153:1739-48.
6. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: an update. Am J Respir Crit Care Med 1998;157:S1-53.
7. Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda (MD): National Heart Lung and Blood Institute/World Health Organization Workshop Report; 1995. Publication no. 95-3659.
8. British Thoracic Society. The British guidelines on asthma management. Thorax 1997;52(suppl 1):S1-21.
9. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Washington (DC): National Institutes of Health; 1997. NIH Publication no. 97-4051.
10. 2-agonist terbutaline with an inhaled steroid in newly detected asthma. N Engl J Med 1991;325:388-92.
11. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
12. Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991;143:1317-21.
13. Levy ML, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 1996;51:1087-92.
14. Juniper EF, Kline PA, Vanzielegmem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991;87:483-9.
15. 2-agonists on lung function, airway responsiveness and symptoms in children with asthma. Am Rev Respir Dis 1992;146:547-54.
16. Waalkens HJ, van Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, et al. Cessation of long-term treatment with inhaled corticosteroids (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993;148:1252-7.
17. Ilangovan P, Pedersen S, Godfrey S, Nikander K, Novisky N, Warner JO. Nebulised budesonide suspension in severe steroid-dependent preschool asthma. Arch Dis Child 1993;68:356-9.
18. Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield AE, O'Byrne PM, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1412-8.
19. Dompeling E, Van Schayck CP, Molema J, Folgering H, van Grusven PM, van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992;5:945-52.
20. Haahtela T, Järvinsen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.
21. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;5:369-72.
22. Selroos O, Pietinalcho A, Löfroos A, Riska A. Effect of early and late intervention with inhaled steroids in asthma. Chest 1995;108:1228-34.
23. Ernst P, Spitzer WD, Suissa S, Cockroft D, Habbick B, Horwitz RI, et al. Risk of fatal and near fatal asthma in relation to inhaled corticosteroid use. JAMA 1992;268:3462-4.
24. Barnes PJ. Inhaled glucocorticoids: new developments relevant to updating the Asthma Management Guidelines. Respir Med 1996;90:379-84.
25. Malo J, Cartier A, Merland N, Ghezzo H, Burke A, Morris J, et al. Four-times-a-day dosing frequency is better than twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis 1989;140:624-8.
26. Jones AH, Langdon CG, Lee PS, Lingham SA, Nankani JP, Follows RMA, et al. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med 1994;88:293-9.
27. Otulana BA, Varma N, Bullock A, Higenbottam T. High dose nebulized steroid in the treatment of chronic steroid-dependent asthma. Respir Med 1992;86:105-8.
28. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
29. Woolcock AJ, Barnes PJ. Asthma: the important questions-part 3. Am J Respir Crit Care Med 1996;153:S1-31.
30. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8.
31. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma [In Process Citation]. Eur Respir J 1997;10:2754-60.
32. Virchow J, Hassall SM, Summerton L, Klim J, Harris A. Reduction of asthma exacerbations with zafirlukast in patients on inhaled corticosteroids. Eur Respir J 1997;10(suppl 25):420S.
33. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-induced bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993;147:1472-6.
34. Barnes PJ, Jonsson B, Klim J. The costs of asthma. Eur Respir J 1996;9:636-42.
35. van Schayk CP, Dompeling E, Rutten MP, Folgering H, van den Boom G, van Weel C. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995;107:1199-205.
36. Hill SJ, Tattersfield AE. Corticosteroid sparing agents in asthma. Thorax 1995;50:577-82.
37. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchameier AD, Bucher BL. A double-blind study of troleandamycin and methylprednisolone in asthmatic patients who require daily corticosteroids. Am Rev Respir Dis 1993;147:398-404.
38. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152:125S-40S.
39. Szefler SJ, Leung DY. Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Eur Respir J 1997;10:1640-7.
40. Leung DYM, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β. J Exp Med 1997;186:1567-74.
41. Adcock IM, Lane SJ, Brown CA, Lee TH, Barnes PJ. Abnormal glucocor-ticoid receptor/AP-1 interaction in steroid-resistant asthma. J Exp Med 1995;182:1951-8.
42. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:218-20.
43. Adcock IM, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor trans-repression and transactivation. Br J Pharmacol 1998 In press.
44. Vayssière BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997;11:1245-55.
45. Barnes PJ. New drugs for asthma. Clin Exp Allergy 1996;26:738-45.